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ABSTRACT 
“Smart” hydrogels are an emerging class of biomaterials that respond to multiple 
external stimuli and investigated for a range of biomedical applications, including 
therapeutic delivery, and regenerative engineering. Stimuli-responsive nanogels based on 
thermoresponsive polymers such as poly(N-isopropylacrylamide) (PNIPAM) and 
magnetic nanoparticles (MNPs), are developed as “smart carriers” for on-demand delivery 
of therapeutic biomolecules via magneto-thermal activation. However due to their small 
size and systemic introduction, these PNIPAM/MNPs nanogels result in limited control 
over long-term, localized therapeutic delivery.  
Here, we developed an injectable nanoengineered hydrogel loaded with 
PNIPAM/MNPs for localize on-demand delivery of therapeutics (doxorubicin (DOX)). 
We have engineered shear-thinning and self-recoverable hydrogels by modulating 
crosslinking density of our methacrylated gelatin (GelMA) network. PNIPAM/MNPs 
nanogels loaded with DOX were entrapped within the GelMA pre-polymer solution prior 
to crosslinking. The temperature and magnetic field dependent release of loaded DOX was 
observed from the nanoengineered hydrogels (GelMA/(PNIPAM/MNPs)). The in vitro 
efficacy of DOX released from injectable nanoengineered hydrogels was investigated 
using preosteoblast and osteosarcoma cells. Overall, these results demonstrated that the 
injectable nanoengineered hydrogels can be used for on-demand and localized therapeutic 
delivery for biomedical applications. 
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I. INTRODUCTION AND LITERATURE REVIEW 
 
Osteosarcoma (OS), is a type of cancer that causes tumors in bone tissue that, like 
most cancers, can metastasize and severely increase mortality rates. OS mainly affects 
adolescents and teens. The 5-year survival rate changes from 60% to 15% if the tumor 
metastasizes. [1] The standard course of treatment for patients suffering from OS, like 
many types of cancer, includes surgical intervention to remove the tumor and aggressive 
chemotherapeutic or radiation treatment plans. Most of these current therapies may only 
delay the progression of tumor growth, and the effect of these treatments falls short of a 
cure, resulting in limited management without eliminating the disease. During surgical 
intervention, there is no guarantee that all tumor cells have been removed and such 
invasive procedures could expose tumor cells into circulation thus forcing a metastasis to 
occur.  
In addition to a complex treatment plan, surgery and chemotherapy is expensive. 
Time at chemo clinics as well as paying for chemotherapeutics and catheter devices are 
costly. Just the office visits alone to chemotherapy and radiation therapy cost an average 
of $30,000 per therapy. A range of therapies including use of ultrasound, gene delivery, 
and macromolecules is currently proposed for OS to improve upon the standard. 
Unfortunately, none of these therapies have translated into a new standard for clinical 
practice. Many research groups have utilized the chemotherapeutic drug Doxorubicin 
(DOX) as a model drug in drug delivery for cancer treatment. DOX has been shown to 
intercalate with DNA and trigger activation of cytotoxic pathways such as the Bcl-2/Bax 
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apoptosis pathway. [2] Local delivery of DOX is crucial for optimal cancer treatment. 
Typical chemotherapeutic treatment is systemic and has many potential side effects such 
as heart damage, nerve damage, bleeding urine, infertility, and liver and kidney damage. 
Systemic chemo also relies upon the fact that tumors have leaky vasculature that will allow 
for the majority of the drug to affect the tumor sites. Therefore, there is a critical need to 
develop effective therapies to locally deliver DOX in a controlled and triggered manner 
to prevent tumor regrowth and other side effects that can occur with standard clinical 
treatments.  
Stimuli-responsive hydrogels can be designed to respond to external stimuli such 
as changes in temperature, pH, light, and ultrasound.[3-7] Hydrogels that experience 
physio-chemical changes due to external stimuli have great potential in the field of non-
invasive and remote controlled therapies. [7] However, the use of these external stimuli 
(temperature, pH, light, and ultrasound) limits the applications of these responsive 
hydrogels systems to specific tissue regions. For example, thermo-responsive hydrogels 
can be used for skin-deep penetration, where external heating can be applied, while pH-
responsive hydrogels can be used in tissue with specific pH ranges. Hydrogels responding 
to ultrasound waves and near-IR radiations have limited penetration ability due to high 
diffraction and absorption ability of tissues. To engineer a versatile stimuli-responsive 
system, nanoparticles that can generate stimuli to control the response of polymeric 
network are designed. These “smart hydrogels” are an emerging class of biomaterials that 
respond to multiple external stimuli and are investigated for a range of biomedical 
applications, including therapeutic delivery, bioimaging and regenerative engineering. 
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Magnetic nanoparticles (MNPs) responding to alternating magnetic fields (AMF) 
have been shown to generate heat due to its superparamagnetic nature. Due to this 
characteristic, MNPs are extensively used as magnetic contrast agents to improve imaging 
resolution for magnetic resonance imaging (MRI) as well as hyperthermia treatments.[8-
10] By combining these MNPs with thermoresponsive polymers, a safe, deep-tissue 
response can be elicited to control the material behavior. These magneto-thermo 
responsive nanomaterials can be designed for “on-demand” therapeutics delivery and MRI 
sensing. Such responsive materials are sometimes utilized for systemic treatment of cancer 
by delivery to tumor sites through leaky vasculature, while others can be made as a 
controllable, biocompatible fixative to maintain long-term resolution of MRI scanning. 
[11, 12] 
 
I.1 Magnetic Nanoparticles Used in Nanocomposites for Biomedical Applications 
Among different types of MNPs, ferromagnetic and superparamagnetic 
nanoparticles (Table 1) are extensively investigated for biomedical applications. [10, 13-
17]  Most often superparamagnetic MNPs are less than 30 nm in diameter. [18] Under 
alternating magnetic fields, superparamagnetic MNPs produces heat due to Brownian and 
Néel relaxation hyperthermia and occurs whenever the magnetic moment in the cores of 
SPM particles changes direction with high frequency. Brownian relaxation occurs in 
addition to Neel relaxation and is caused from movement of the entire SPM particle. For 
these relaxation mechanisms to occur, the particles must be superparamagnetic and single 
domain and therefore less than 30 nm. This hyperthermic potential is utilized for ablative 
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applications on tissue sites of interest. [8] Aggregation, corrosion, and loss of magnetism 
occur over time with magnetic nanoparticles. [9] In order for ferrous nanoparticles to stay 
in solution for a long period of time, synthesis usually includes a step for functionalizing 
each nanoparticle with molecules such as PEG, citric acid, oleic acid, or other molecules. 
[19]  
Magnetite and hematite are the most commonly utilized ferromagnetic 
nanoparticles for biomedical applications due to their biocompatibility, potential for 
stability, and high magnetization ability.  Magnetite, which has the chemical formula 
Fe3O4 and may also be written as Fe2O3.FeO, contains Fe3+ as well as Fe2+ ions ordered 
unequally, which gives rise to a net magnetization ability. This high magnetization caused 
by its ferromagnetic and superparamagnetic capabilities makes it a great material for 
magnetic hyperthermia. Magnetite is commonly utilized in research as an MRI agent, 
hyperthermic agent, component in drug delivery constructs, as well as for scaffold-free 
tissue culture. [9, 19-21] Hematite has the formula Fe2O3 and has been recently 
functionalized with fullerenes such as C60 for potential use in drug delivery, non-viral gene 
delivery, and MRI contrast mediums. [22-24] γ-Fe2O3 is not as magnetically responsive 
as magnetite so in literature it is often incorporated into magnetic alloys such as the 
fullerene example. Another iron-containing nanoparticle used in biomedical application is 
FePt. FePt’s ability to be surface modified like magnetite and hematite allows for various 
applications such as targeted drug delivery, photochemical therapy, biosensing, and 
imaging. [15, 25, 26] Finally, CoFe containing nanoparticles are also researched and have 
relevance in bioimaging and drug delivery applications. [13, 27, 28] Superparamagnetic 
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iron-containing nanoparticles such as these are utilized in many biomedical applications 
and have potential to become part of new clinical standards due to its lack of a significant 
difference in cell toxicity with varying concentrations. [29, 30] 
 
Table 1: Summary of Common Magnetic Nanoparticles Used in Magnetically-Responsive Nanocomposites for Biomedical Applications 
Material (# Papers as of 3/2016) Magnetic Behavior Utilized Common Biomedical Applications 
Fe3O4 (Magnetite) (1,004) ferromagnetic, superparamagnetic MRI contrast mediums, hyperthermic agents, drug delivery, cell migration 
γ-Fe2O3 (Hematite) (227) ferromagnetic, superparamagnetic MRI contrast mediums, drug delivery 
FePt (88) ferromagnetic, superparamagnetic Photothermal cancer treatment, hyperthermic agents, cell migration 
CoFe (24) ferromagnetic, superparamagnetic MRI contrast mediums, drug delivery 
 
I.2 Thermoresponsive Polymers Used in Magnetically-Responsive Nanocomposites 
for Biomedical Applications 
Thermoresponsive hydrogels are found in either hydrophilic or hydrophobic states 
dependent upon temperature. It is these types of polymers that are used to fabricate 
magnetically responsive hydrogels. By using factors such as the Neel and Brownian 
relaxation mechanisms discussed above, magnetic nanoparticles suspended or 
encapsulated by thermoresponsive hydrogels can act as local sources of heat to cause the 
thermal response. When activation of these magnetic nanoparticles ceases, the creation of 
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heat ceases and temperature returns to the ambient temperature surrounding the polymer. 
In this way, the reversibility of thermoresponsive hydrogels can be controlled with 
magnetic fields instead of with heating elements. Because of thermoregulation in human 
bodies, any transition temperature outside of a narrow range within body temperature (37 
C) would require a clinician to cause patients to go under hypothermia or hyperthermia, 
which has potential for organ failure and other complications. When utilizing nanosized 
materials, temperature increases that occur locally would not cause these pathological 
temperature conditions. Therefore, a secondary response that allows localized, controlled 
increase in temperature in nanosized medical applications is highly researched. Various 
polymers with these properties have been utilized for biomedical purposes and are 
summarized in Table 2. 
One such polymer, poly(N-isopropylacrylamide) (PNIPAM), is heavily researched 
for thermoresponsive applications. [7, 31-35] Common applications of to this polymer 
include drug delivery, cell sheet engineering, tissue engineered scaffolds, and DNA 
sensing. [36-41] Poloxamer is the generic name for tri-block copolymers consisting of two 
blocks of poly(ethylene oxide) (PEO) with a block of poly(propylene oxide) (PPO) in 
between. PEO’s biocompatibility and shielding from protein adhesion are well researched 
due to the highly hydrophilic nature of this polymer. [42, 43] Poloxamers are sold 
commercially as Pluronics® by the chemical manufacturing company BASF. 
Poly(organophosphazene) (PPZN) is a family of macromolecules first isolated in the 
1960s and are found to exhibit a reversible sol-gel transition with a change in temperature. 
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More recently, there have been biocompatible versions that can exhibit this change in a 
physiological temperature range. [28, 44]  
 
Table 2: Summary of Common Thermoresponsive Polymers Used in Magnetically-Responsive Nanocomposites for Biomedical Applications 
Material (# Papers as of 3/2016) 
Chemical Structure Thermal Transition Behavior 
Common Biomedical Applications 
PNIPAM (28,729) 
 
LCST/VPTT Drug delivery, cell sheet engineering 
Poloxamer (54) 
 
CMT Drug delivery, cancer therapy, surfactants for other syntheses 
Poly(organophosphazene) (12) 
Varies;  
LCST/VPTT  Tissue engineered scaffolds, in situ gelation, drug delivery, long term MRI contrast agent 
 
I.3 Magnetically Triggered Nanocomposite Hydrogels for Drug Delivery 
Researchers utilize nanocomposites for controlled drug delivery for combating 
drug uptake issues, optimizing time within the therapeutic threshold, as well as enhancing 
biocompatibility of healthy tissues. Many drugs are water insoluble, have too fast of a 
half-life, and can cause potentially serious side-effects. All pharmaceuticals require the 
correct dosage to maintain a therapeutic threshold. Many analgesics utilize delayed release 
or diffusion kinetics to properly deliver drugs within this threshold, but are systemic in 
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nature and typically have to get above the threshold into slightly toxic conditions to allow 
for diffusion out of the system and stay in the therapeutic range for a longer amount of 
time. This is partially responsible for many pharmaceuticals’ harmful side effects. Also, 
having a drug delivery vehicle small enough to enter into tissue is beneficial for increasing 
uptake and getting the drug payload to the tissue sites of interest, as seen in smaller 
molecules that exist systemically. Biocompatibility is another issue that limits options for 
the application of drug delivery. Having a controlled system requires no interference from 
the immune system. When applying nanocomposite systems for drug delivery or other 
applications, interference from the immune system will cause digestion of the construct 
by macrophages and cause either burst release or prevent release by fibrous encapsulation 
that covers foreign bodies too large to be uptaken in layers of fibroblasts which close it 
off from the rest of the body. In this section, we explore ways that researchers have 
overcome these limitations with the addition of two or more components to the magnetic 
nanoparticles. 
In recent years, Jaiswal et al. synthesized Fe3O4 nanoparticles conjugated with 
either poly(ethylene glycol) (PEG) or polyhedral oligomeric silsesquixone (POSS). [45] 
These particles were then encapsulated by copolymerizing a layer of PNIPAM to produce 
a nanocomposite hydrogel system for in vitro release of incorporated Doxorubicin with 
and without presence of an AMF field. At temperatures above the material’s intrinsic 
volume phase transition temperature (VPTT), the PNIPAM expels its water content to 
form globules and precipitates out of solution. This occurs because hydrophobic 
constituents (isopropyl) of the polymers forming the hydrogel become entropically-
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favored over the hydrogen bonding from hydrophilic components, resulting in thermally 
induced conformational changes. PNIPAM has its VPTT at 33-35 C, and in order to 
increase or decrease the transition temperature it can be copolymerized with hydrophilic 
or hydrophobic polymers, respectively. The process of hydrophilic to hydrophobic 
transition at VPTT is reversible, which enables its usage in carrying and releasing aqueous 
soluble therapeutics as a controlled drug delivery system. These nanocomposites were 
around 200 nm in size and relatively spherical. This three component system exhibited 
VPTT behavior at around 40 C which allowed for controllable release of encapsulated 
cargo to occur from magnetic hyperthermia alone instead of burst release once exposed to 
body temperature. Different incubation times of the nanocomposites with their tested 
HeLa cell line, as well as different AMF exposure times were explored to discover optimal 
release percentage of encapsulated DOX. It was seen that a 48 hour incubation period after 
1 hour of magnetic field exposure allowed for the highest release at close to 40% or 10µg 
of DOX. This level of release allowed for a significant decrease in cell viability by close 
to 80%, which is expected with DOX exposure to a cancer cell line. Jaiswal also noted 
that no macroscopic temperature change was exhibited from the samples during RF 
exposure, which is beneficial for preventing unwanted tissue ablation. 
With a low mortality rate, when an OS tumor is found, surgery is a standard option 
for treatment. However, like all surgeries, there are always risks involved. A potential risk 
that can occur in that during tumor excision, some cells can venture elsewhere in the body 
and develop other tumors. [46] Therefore, a current standard is for intravenous injection 
of chemotherapeutics or radiation therapy to be the sole or secondary source of treatment. 
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It is well researched that tumor sites typically have ‘leaky’ vasculature, or vasculature that 
allows for easier movement into the surrounding interstitial tissue space. [47-50] Make 
use of this knowledge, intravenous approaches statistically should have a greater chance 
of affecting tumor sites than healthy interstitial tissue. 
However, a common problem occurs with free-roaming nanocomposites in 
vasculature or free tissue space due to the reticuloendothelial system. [11, 29, 51] This 
system involves phagocytic immune cells located in connective tissue throughout the 
body. By having nanosized particles with loaded-therapeutics that are able to be uptaken 
so readily by cells, these phagocytic cells also uptake them and prevent delivery to the 
desired tissue site. In addition to this prevention, if loaded with chemotherapeutics, such 
phagocytic cells as the Kupffer cells in the liver, pulmonary alveolar macrophages in the 
lungs, and glomerular mesangial cells in the kidneys all would entrap these cytotoxic drugs 
in healthy tissue sites and could cause cell death of non-tumor cells. It was therefore a 
concern for us to maintain spatial control in addition to temporal control of delivery of 
therapeutics. 
Gelatin is a natural polymer made of denatured collagen. Found in many food 
products, this material has applications in the biomedical field due to its injectability and 
ability to mimic extracellular matrices. This material has been utilized for injectability 
potential for several biomedical applications including a vessel for wound healing. [52] 
By methacrylating gelatin, researchers have created a stronger, crosslinked gel that can be 
incorporated with nanoparticles for various biomedical purposes. Methacrylated gelatin 
has also been shown to be injectable and maintain RGD binding sequences to assist in cell 
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adhesion. [53-56] Therefore, addition of gelatin-based hydrogels allow for fixity for 
nanoparticles as well as promoting cell attachment from cells at desired tissue sites to 
facilitate therapeutic delivery. 
A widely popular thermo-responsive polymeric hydrogel poly(N-
isopropylacrylamide) was copolymerized with acrylamide and employed for this 
application due to its biocompatibility and stimuli-responsive nature [57]. By coating the 
MNPs with this thermoresponsive polymer shell, a nanogel drug reservoir with 
controllable release was made. The incorporation of MNPs allow for magnetic 
hyperthermia to heat surrounding stimuli-responsive material. Utilizing methacrylated 
gelatin allowed the construct to gain the spatial control we desired and reduced chances 
of drug-loaded nanocomposites from leaving the targeted tissue site. The nanogels were 
encased in photo-polymerizable gelatin matrix (namely gelatin methacrylate or GelMA) 
and injectability was proven possible as well as maintained viability of different cell types. 
Therefore, we offer a biocompatible, minimally-invasive tool where the use of external 
alternating magnetic fields remotely can induce the release of loaded drug in a controlled 








II. MATERIALS AND METHODS 
 
II.1 Materials 
 Ammonium hydroxide solution (NH4OH, ACS reagent, 28-30% NH3 basis), 
ammonium persulfate (APS, ACS reagent, 98+%), citric acid (99%), ferric chloride 
hexahydrate (FeCl3.6H2O, ACS reagent, 97%), ferric chloride tetrahydrate (FeCl2.4H2O, 
ReagentPlus®, 98%), gelatin from porcine skin (gel strength 300, Type A), N,N’-
Methylenebis(acrylamide) (BIS, 99%), N-isopropylacrylamide (NIPAM, 97%), and 
sodium metabisulfite (SBS, 99+%) were all purchased from Sigma-Aldrich. 
Doxorubicin.HCl (DOX, 98%) was purchased from Cayman Chemical. Acrylamide (AM, 
98+%) was purchased from Alfa Aesar. Sodium dodecyl sulfate (SDS, Biotechnology 
grade) was purchased from Amresco. Lithium acylphosphinate (LAP) photoinitiator was 
kindly provided by Dr. Daniel Alge’s laboratory at Texas A&M University (College 
Station, TX). All chemicals were used as received without further purification or 
processing. Megaohm water (17.8 MΩ.cm) was used for all experiments.  
 
II.2 Synthesis of MNPs and Nanogels 
Citric acid coated MNPs were synthesized via co-precipitation method as 
described previously. [58]  In short, FeCl3.6H2O and FeCl2.4H2O solutions were mixed 
together and N2 purged for 30 minutes. An oil bath was heated to 70 C for 30 minutes and 
then a solution of NH4OH was added dropwise and a black precipitate was formed 
immediately. After 30 minutes, a solution of citric acid was added and the temperature 
 14 
 
was increased to 90 C and left for 1 hour. The MNP solution was left to cool to RT and 
magnetically separated from the solution for washing 5 times with DI H2O. The 
concentration of the washed solution was determined by measuring iron content in the 
resultant product using ion coupled plasma atomic emission spectroscopy (ICP-AES). 
Their magnetization ability was measured via superconducting quantum interference 
device (SQUID). 
These MNPs were then embedded within poly(N-isopropylacrylamide-co-
acrylamide) (PNIPAM-co-AM) via free radical polymerization method described 
elsewhere to make PNIPAM-co-AM/MNPs (nanogels). [45, 59] A solution of NIPAM, 
AM and MNPs for nanogels synthesis) were added to the flask and stirred and N2 purged 
for 30 minutes. BIS and SDS solutions were each added dropwise to the flask and purged 
for another 30 minutes. Then the oil bath was heated to 70 C and APS and SBS solutions 
were each added dropwise. The reaction was allowed to continue for 5 hours and returned 
to room temperature. In order to isolate nanogels, magnetic separation overnight was 
performed. The solution was then freeze-dried for storage.  
 
II.3 Characterization of Nanogels 
Hydrodynamic particle size, VPTT determination, and zeta potential were 
performed with a Zetasizer Nano ZS (Malvern Instruments, UK). ATR-FTIR 
measurement was performed with an FTIR spectrometer (ALPHA, Bruker, USA) and 
samples were of air-dried MNPs, NIPAM, AM, lyophilized PNIPAM-co-AM, and 
lyophilized nanogels. To view particle shape and confirmation of a presence of an MNP 
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core in the nanogels, TEM was performed on MNPs and nanogels (JEM-2010, JEOL, JP). 
Nanogels were also imaged with SEM (JSM-7500F, JEOL, JP). TGA measurement was 
performed with a TGA Q50 (TA Instruments, DE) to confirm copolymerization ratio and 
weight percentage of MNPs in nanogels.  
 
II.4 Synthesis of Gelatin Methacrylate 
Gelatin methacrylate with a methacrylation degree of 80% was synthesized as 
discussed previously. [54] The final solution of 80% methacrylated gelatin methacrylate 
(GelMA) was dialyzed for 7 days, filtered with quantitative filter paper and then freeze-
dried for storage purposes. Lyophilized GelMA was rehydrated in a 2.2 mM LAP solution. 
LAP was chosen as the photoinitiator due to problems with photobleaching of DOX when 
we utilized more common photoinitiators such as Irgacure® 2959. [60] A UV light source 
(Omnicure S2000, Lumen Dynamics, Canada) set to an intensity of 10 mW/cm2 was used 
for gel crosslinking. 
 
II.5 Preparation of Nanocomposite Hydrogels 
Water-swollen nanogels were entrapped within a gel for rheological studies. 5 mg 
of nanogels were suspended in 1 mL of GelMA and UV crosslinked. To perform stress, 
frequency, and shear stress sweeps, a 1 mm thick sheet was crosslinked in a sandwich 
mold and 7 mm diameter punches were made. In addition to this, extruded gels of 1 mL 
of gel from a syringe with an 18G needle were tested for comparison with stress and 
frequency sweeps. The extruded gels were also tested for cyclic recoverability after high 
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shear (100%). 5 mg of drug-loaded nanogels were well-dispersed and entrapped within a 
UV-crosslinked gel for release experiments. In order to make nanogels dispersed in the 
gel, the pellet of washed DOX-loaded nanogels was re-suspended and vortexed within a 
100 µL solution of GelMA + LAP, after which the nanocomposite precursor was exposed 
to UV light.  
 
II.6 Rheological Studies 
Shear stress and frequency sweeps were completed on an Anton Paar Physica 
MCR 301 rheometer (Anton-Paar GmbH, Austria).  All experiments were completed at a 
physically relevant temperature (37 °C) using a humid atmosphere using a solvent trap. 
Shear rate sweeps were performed from 0.1-100 1/s to determine the injectable 
characteristics.  The linear visco-elastic region of the samples were determined via a 
frequency sweep executed at 1 Pa between 0.1-100 Hz.  Shear stress sweep was performed 
at 1 Hz between 0.0-100 Pa. Frequency and shear stress sweeps were completed on 
circular sheets of sample as well as extruded samples. 
 
II.7 Encapsulation of DOX in Nanogels and Release 
DOX absorbance and fluorescence was measured with an Infinite® 200 PRO 
microplate reader (Tecan, Switzerland). Various weights of lyophilized nanogels (2.5, 5, 
10, and 15 mg) were re-suspended in 1 mL solutions of 100 µg DOX to obtain optimal 
loading. In addition to this, 5 mg of lyophilized nanogels were also rehydrated in 1 mL 
solutions of varying concentrations of DOX (25, 50, 100, 150 µg/mL). After overnight 
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swelling at 4 C, the nanogels were centrifuged and washed 4x with chilled DI H2O. The 
DOX concentration loaded within the nanogels was found via encapsulation efficiency 
(EE) calculations (Equation 1). 
ܧܧ ሺ%ሻ =  ௪௘௜௚  ௢௙ ௙௘௘ௗ ௖௔௥௚௢ି௪௘௜௚௛௧ ௢௙ ௨௡௟௢௔ௗ௘ௗ ௖௔௥௚௢௪௘௜௚௛௧ ௢௙ ௙௘௘ௗ ௖௔௥௚௢ ∗ 100 (Equation 1) 
Weight of the unloaded cargo was found by measuring and summating fluorescence of the 
supernatant after each round of centrifugation.  
To measure release of nanogels, 5 mg of 100 µg/mL loaded and washed nanogels 
were suspended in 1 mL of 1X PBS inside of a floating dialysis tube as sink-reservoir 
system using dialysis membrane (Mol. Wt. ~ 10,000 Da). 1 mL was taken at timepoints 
of various hours, and then refilled with 1 mL of 1X PBS after each timepoint. These 
experiments were done at 37 C and 50 C. Fluorescence was then measured using the 
microplate reader. Cumulative release was then calculated and plotted versus time. 
 An Ambrell® EasyHeat 2.4 kW induction heating system (Ambrell, UK) was 
utilized for generation of an AMF to be exposed to the nanocomposite system at RT. The 
usage of this generator was made possible with help from Dr. Ibrahim Karaman’s 
laboratory at Texas A&M University. A 0.25 inch (0.635 cm) thick copper coil of 0.5 inch 
(1.27 cm) inner radius and 6 turns was utilized with a current of 400 A alternating at 170 
kHz to produce a magnetic field of 2.99x104 A/m (0.0375 T). The magnetic strength 
required to produce a release from our system was calculated using the Biot-Savart Law 
(Equation 2),  
ܪ = ே௜√ସோమା௅మ  (Equation 2) 
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where H is magnetic field strength in A/m, N is number of turns, i is the current in 
Amperes, R is the inner coil radius in meters, L is the coil length in meters. [61] A DOX-
loaded nanocomposite 100 µL droplet was submerged in 1 mL 1X PBS within an 
Eppendorf tube. A control tube was left at RT, while the other was exposed to the AMF. 
After 1 hour of exposure, sample and control tubes were centrifuged and the PBS solution 
was extracted and fluorescence measured in order to obtain amount of DOX released. 
II.8 2D Cell Exposure
 Mouse preosteoblasts (MC3T3-E1 Subclone 4, ATCC) were cultured in normal 
growth media composed of α-minimal essential media (AMEM, Hyclone), 16.5% fetal 
bovine serum (Atlanta Biologicals, USA), and 1% penicillin/streptomycin (100 U/100 
µg/mL, Gibco). Similarly, mouse osteosarcoma cells (RFP-MOS-J) were cultured in 
Dulbecco’s modified eagle media (DMEM, Hyclone), 10% fetal bovine serum (Atlanta 
Biologicals, USA), and 1% penicillin/streptomycin (100 U/100 µg/mL, Gibco). RFP-
MOS-J cell line was kindly provided by Dr. Roland Kaunas’ laboratory at Texas A&M 
University. Media was changed every 3-4 days and cells were passaged at ~70-80% 
confluency.  
 To test the cytotoxicity of doxorubicin, an MTT assay (MTT assay Kit) was 
performed with the RFP-MOS-J cell line. Cells were seeded at a density of 10,000 cells 
per well in a 96 well plate and allowed to proliferate for 24 hours. Cells were then treated 
with varying concentrations of DOX for 6 hours. After the 6 hour treatment, cells were 
washed with sterile 1X PBS (PBS, Corning) and incubated in normal growth media for 48 
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hours. Next, 100 µL of fresh media was added to the samples along with 10 µL of MTT 
reagent. The samples were then incubated at 37°C for 3 hours. After incubation, media 
and MTT reagent were removed and the resulting crystal was dissolved with a 100 µL of 
a dimethyl sulfoxide (DMSO), isopropyl alcohol (IPA) solution (DMSO:IPA). The 
samples were well mixed and the absorbance was read at 540 nm. The IC50 curve for 
doxorubicin exposed to MOS-J cells was found through normalization. Similarly, 
suspensions of 5mg nanogels and DOX-loaded nanogels were exposed to the RFP MOS-
J and MC3T3 cells for 6 hours and the cytotoxicity was determined using the same 
treatment procedure and MTT assay.  
 In addition, a Live/Dead assay was performed on both cell lines treated with 
solutions of DOX, the 5mg nanogels, and DOX-loaded nanogels. The Live/Dead reagent 
was prepared using ethidium homodimer and Calcein AM (Santa Cruz Biotechnology Inc, 
USA). After cells had been subjected to similar treatment conditions discussed above, they 
were washed with 1X PBS and incubated at 37°C with the Live/Dead reagent for 30 
minutes. The samples were then washed with 1X PBS and an epifluorescence microscope 
(TE2000-S, Nikon, USA) was used to image.  
 Finally, the cytotoxicity of the nanocomposite was tested using the RFP MOS-J 
cells. Cells were seeded into a 24 well plate and allowed to adhere for 24 hours. To isolate 
the results of the study to show in vitro release behavior, transwell inserts were used 
instead of direct placement in wells in order to expose the cells to the GelMA matrix for 
6 hours. After 6 hours the inserts were removed and cells were incubated for 48 hours 
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similar to the previous viability studies. Live/Dead and MTT assays were performed on 
the samples.  
 Uptake of DOX loaded nanogels after 6 hours in preosteoblasts was observed using 
an epifluorescence microscope (TE2000-S Nikon, USA). Prior to imaging, samples were 
fixed with 2% glutaraldehyde in 1X PBS for 20 minutes, treated with 0.1% Triton-X100 




III. RESULTS AND DISCUSSION 
 
III.1 Characterization of MNPs and Nanogels 
In order to identify our nanoparticle components within the nanocomposite system, 
we performed various characterization techniques. Low polydispersity was seen when we 
performed dynamic light scattering on our citric acid-capped Fe3O4 magnetic 
nanoparticles (MNPs) as well as the PNIPAM-co-AM coated MNPs. This showed that we 
had very little aggregation issues, which was beneficial for good spread of suspension 
within our nanocomposite construct. In the graph shown in Figure 3b, two peaks were 
separately measured and overlayed to show the mean values of 28 nm and 255 nm 
diameters for MNPs and nanogels, respectively. Comparing the mean diameter of MNPs 
to the TEM of these MNPs shows that there was an initial aggregation of 5-10 nm MNPs. 
This behavior is shown in the TEM of the nanogel system where more than one MNP 
makes up the core of each nanogel and matches the size of the results from Dynamic Light 
Scattering (Figure 3a). We believe that this slight aggregation is due to the capping group 
of citric acid not being as stable as some other functionalizing agents such as oleylamine, 
which give monodisperse colloidal MNP solutions. [13] Although the sizing of this MNP 
core is close to the limit of SPM behavior, because each MNP is below the size of the 
aggregate, SPM behavior was expected to remain and was confirmed so by the hysteresis 
loop plotted from our SQUID results which showed a high magnetization of ~65 emu/g 
(Figure 2).  
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DLS of the nanogels showed that the hydrodynamic diameter was low in 
polydispersity at a size of 255 nm (Figure 3b). This is within the range of similar nanogels 
synthesized by Jaiswal et al and other researchers, with many drug-loaded vessels at or 
less than 500 nm still able to be uptaken by cells. [45, 62, 63]  
 
Figure 2 – Hysteresis loop. SQUID showed high magnetization of 65 emu/g for our MNPs.  
A temperature sweep of the nanogels was run to discover the deswelling 
temperature of our nanogels (Figure 3c). As the VPTT was identified as occurring at 45 
C, the size of particles begins to decrease at around 41 C. We opted to use VPTT versus 
the more commonly used LCST to describe this behavior because these are crosslinked 
polymer hydrogels, and because we determined transition temperature via DLS 
temperature trend versus a cloud point method or DSC. [64] By copolymerizing with a 
hydrophilic monomer, hydrogen-bonding interactions dominated more and required a 
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higher energy for hydrophobic interactions to dominate. These results are similar with the 
phase transition measured in Zhang et al for a similar copolymer ratio. [59] TGA in Figure 
3c showed a copolymerization ratio of approximately 80:20 (NIPAM:AM) as desired to 
increase the VPTT. The weight of MNPs within the nanogel sample was approximately 
15%. This decrease still occurs above normal body temperature (37 C), so we accepted 
the copolymer ratio and proceeded with experiments utilizing this nanogel synthesis. 
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Figure 3 - MNP and nanogel characterization results. (a) TEM and SEM of MNPs and nanogels. (b) DLS and Zeta Potential. MNPs had a mean of 28 nm with a PDI of 0.40 and nanogels were of a mean of 255 nm with a PDI of 0.21. The zeta potential of the nanocomposite showed a more negative z.p. than just GelMA. (c) VPTT was determined to be 45 C from a DLS temperature sweep and copolymer determination was approximately 80:20 (PNIPAM:AM) from TGA and it also showed an MNP 
 wt% of 15%. 
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III.2 Rheological Studies 
Using an injectable system requires characterization of its material behavior before 
and after injection into our tissue site of interest. In order to characterize the mechanical 
properties of our nanocomposite, rheological studies were performed on 5 wt% gels and 
gels with 5 mg nanogels added (nanocomposite). Frequency sweep between 0.1-10 Hz 
was performed on all samples, determining the linear visco-elastic region of the samples.  
There was a slight increase in the storage modulus with frequency > 5 Hz which could be 
attributed to bond breakage within the GelMA backbone.  Interestingly, we observed no 
difference between samples containing nanogels and those without regardless of 
concentration. Addition of nanoparticles into injectable hydrogel constructs has been 
investigated by researchers. [52, 65] When adding silica nanoparticles to gelatin, 
Gaharwar et al. observed an increase in storage moduli with higher nanoparticle content. 
This difference from what is seen in literature suggests that our nanogel amount in the 
nanocomposite is not high enough to make a significant difference in gel strength. 
Although there was no significant rheological difference shown between gels and 
nanocomposites, zeta potential confirmed nanogel presence in our nanocomposite due to 
a more negative zeta potential than just our methacrylated gelatin due to the negatively 
charged MNPs; therefore a considerable amount of nanogel was present in the 
nanocomposite (Figure 3b). Stress sweeps show similar results as frequency sweeps.  In 
each, the plateau is approximately 200 Pa (Figure 4 a, b). Our data suggests that the small 
amount of nanogels and limitations due to physical entrapment within the GelMA led to 
limited changes in internal stress and therefore no pronounced mechanical variation. 
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PNIPAM has been well characterized rheologically by itself, though from our 
investigation we are one of the first to use it is such a fashion as a filler material. [66] The 
low storage modulus of our gel is recognized, but due to the high affinity of cell adhesion 
on gelatin hydrogels, we preferred a weaker substrate that would not cause proliferation 
of cancer cells after injecting our nanocomposites to tumor sites. [67] 
Due to the end goal of being able to inject our material, we then investigated how 
the sample behaves under high shear to determine the yield stress of the material. When 
passing a material through a syringe needle during injection into tissue sites, a fluidic flow 
is achieved through introduction of high shear stress. For a solid, crosslinked gel like ours, 
we expected a return to a gel state from its more fluid flow. Shear rate sweeps from 0.1-
100 1/s indicated that all samples are shear-thinning: the sample viscosity decreased with 
increasing shear rate (Figure 4c). Our data, both experimentally and in practice, suggest 
that the nanofiller has no effect of the ability to extrude material out of a needle. We further 
investigated recoverability of the sample via application of high shear rate and then no 
shear.  Over 3 cycles, the sample recovers quickly to its pre-sheared storage modulus 
(Figure 4d). To be clinically relevant, thixotropic recoverability samples were crosslinked 
within a syringe and extruded at a rate of 2 mL/min. This ability to recover was comparable 
to thixotropic studies by Gaharwar et al when adding nanoparticles to gelatin matrices. 
[52] It is believed that the weakness of the gel as well as the temperature at which we kept 
our gels at during testing (37 C) were responsible for keeping our nanocomposite 
recoverable and preventing brittle fracture upon injection. 
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The rheological difference between preformed samples tested and extruded 
samples were also investigated (Figure 5). Comparing extruded and non-extruded 
samples, we found no difference in the recoverable behavior, leading to the injectable uses 
of this material. Due to the high shear on our crosslinked gel out of a syringe, we expected 
there might be some bond breakage due to forcing this preformed gel. However, no 
significant difference was shown in storage moduli between preformed and injected 
samples, so rheological studies from Figure 4 a-c of preformed gels are proposed to be 
relevant to the final nanoengineered construct. We anticipate that upon injection, the 
sample will remain within a localized area. Depending on the initial degree of 








Figure 5 – Preformed vs injected gel rheology. Stress sweep performed on equal volumes of preformed discs of 5 wt% gel and extruded strands of 5 wt% gel, with no statistical difference found.  
III.3 Release from Nanogels 
In order to observe release kinetics from our system with and without presence of 
stimuli, we performed thermal and magnetic release studies. First, in order to 
experimentally quantify release from our nanocomposites, calibration on our plate reader 
was performed with varying DOX concentrations within the range expected to be seen 
throughout our studies. The calibration and standard curves of DOX from our plate reader 
can be found in Figure 6. A highly linear trend allowed us to quantify DOX concentration 
from absorbance or fluorescence information. The weight of nanogels and DOX were used 
based from encapsulation efficiency studies shown in Figure 7. 5 mg nanogels rehydrated 
with 100 µg/mL DOX showed to have the best loading content at 42.1±8.1% efficiency 
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(or 42.1±8.1 µg loading), so all release studies were performed with these nanogel and 
DOX weights. This loading efficiency was similar to work shown by Shah et al. [68] We 
believe that this combination of nanogel and DOX concentration was best due to it having 
enough surface area available to load as much DOX as possible. With a Gaussian 
distribution profile, one-way ANOVA was performed followed by Tukey’s multiple 
comparisons test. 100 µg/mL within 5mg of nanogels showed the best encapsulation 
efficiency with significant difference (p<0.05) when comparing 50 and 150 to 100 µg/mL 
DOX. We believe that this decrease after 100 µg/mL was due to supersaturation of the 
DOX solution. When EE of 100 µg/mL was tested, a significant difference between 2.5 
and 5 mg as well as 5 mg and 15 mg nanogel weights was found (p<0.01 and p<0.05, 
respectively). Above 5 mg, this decrease in encapsulation efficiency could be attributed to 
packing of the lyophilized nanogels, which would limit surface area available for uptake. 
Below 5 mg, we found the pellet of DOX-loaded nanogels to be too small to utilize this 
method of encapsulation study and that the concentrations tested were too saturated for 
the amount of nanogels to absorb a considerable amount of DOX. 
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Figure 7 – Encapsulation efficiency results. EE studies on 5 mg nanogels with various DOX solutions and on various nanogel weights with 100 µg/mL DOX solutions.  
After six hours of exposure to a heated environment above the transition 
temperature of the nanogels, 74.6±6.3% of encapsulated DOX was released (Figure 8a). 
For the experiments run at 37 C, release was limited to less than 25%. Comparable studies 
showed similar behavior in release kinetics. [68] This limited release could be due to 
surface adhered DOX not fully within the nanogel, or due to a slight decrease in 
hydrodynamic diameter at 37 C, which was seen via DLS temperature sweep at the 
beginning of the transition temperature range quantified in Figure 3c. However, with a 
plateau after this burst release and the low concentration released from the nanogels, we 
opted to continue using our synthesized nanogels for future experiments. The significantly 
enhanced release (p<0.01) at a higher temperature, particularly above VPTT, confirmed 
the temperature-triggered behavior of the PNIPAM-co-AM shell of the nanogel. 
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An average of 75.1% of the loaded DOX was released from our nanocomposite 
into the PBS bath after 24 hours of thermal exposure above the VPTT (50 C) (Figure 8b). 
A significantly lower (p<0.05) release amount was shown from the 37 C exposed samples. 
Significantly enhanced release in a thermally-triggered environment showed that the fixity 
of the gel slowed release, but a large percentage was still released into the environment 
after a short time range. This delay in release is shown in many papers that utilize 
macroscopic gel matrices for drug release studies. [69] 
An average release of 23.4±1.4% was shown after 1 hour of exposure to the AMF, 
and in the same environmental conditions with no AMF-exposure, a smaller burst release 
of 7.8% was observed (Figure 8c). Release after AMF exposure was lower than similar 
results by Jaiswal et al (~40%), but this is expected to be due to slower diffusion from the 
highly crosslinked gel. [45] Also, our induction heating system had a lower frequency of 
170 kHz than Jaiswal’s experiments (230 kHz) due to limitations in our system. It is also 
worth noting that the field strength utilized for this experiment (0.0375 T) were lower than 
the AMF strength found in commercial MRIs (0.05 to 3 T), so exposure to a larger field 




Figure 8 - Release studies on nanogels and nanocomposites. (a) Release kinetics from nanogels were shown to be significantly different (p<0.01) when exposed to temperatures above the VPTT. (b) Release from nanocomposite also showed significant difference (p<0.05) when exposed to temperatures above VPTT. (c) Nanocomposite was exposed to an AMF at RT for 1 hour and shown to be significantly greater than nanocomposites with no magnetic field exposure.  
A significant difference (p<0.0001) was shown when comparing cumulative 
release after 1 hour for AMF-exposed samples versus thermally exposed samples (Figure 
9). An improved release after 1 hour with magnetic exposure suggests a potentially 
enhanced release profile for our magnetically-responsive nanocomposite. Similar 
observations have been made by other researchers such as Liu et al. in which a significant 
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difference between magnetic and thermal release was shown from their nanogel system. 
[70] In their work, they showed a more pronounced burst release from their magnetically-
triggered nanogels than their thermally-triggered nanogels. Temperature radiated due to 
magnetic hyperthermia could not be evaluated with thermocouple or IR camera due to the 
small weight percentage of magnetic nanoparticles within a low amount of loaded 
nanogels. We believe that this enhanced release could be due to delays in thermal balance 
in our PBS bath studies that potentially delayed the burst releases above the VPTT. Based 
off our data, a triggered release could be observed with magnetic fields in addition to 
temperatures above body temperature. These results proved that our system can be utilized 
for biomedical purposes. 
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Figure 9 – 1 hour release comparison. Nanocomposite cumulative release at 1 hour 
of temperature (37 C, 50 C) and 1 hour of AMF exposure (AMF) showed significant 
difference (p<0.0001) between thermal and magnetic releases. 
III.4 2D Cell Viability
Based off the results from Figure 8a, the “Free DOX” weight chosen was 30 µg 
(or ~75% of our average EE of 42.1 µg) per 1 mL. With this concentration, cell viability 
decreased to approximately 17.7±2.5% of normalized mitochondrial activity. Doxorubicin 
works as an anti-cancer drug by entering the nucleus and intercalating with DNA to stop 
DNA replication and ultimately causes cytostasis. [2] Therefore, free DOX exposure on 
fast-replicating cell types like MOS-J and MC3T3 lines cause significant cell death. 
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To evaluate the viability of the delivery system, in vitro studies utilizing 
preosteoblasts and osteosarcomas were conducted.  First, the IC50 of DOX used to treat 
the osteosarcoma cells was determined to be above 10 µg/mL so a concentration of 30 
µg/mL was acceptable for the remainder of the experiments (Figure 10). RFP-MOSJ cells 
were treated with free DOX, nanogels, DOX-loaded nanogels, gel, and Dox-loaded 
nanocomposites for 6 hours. After 48 hours, live/dead staining showed qualitatively that 
while free DOX caused significant cell death, exposure to nanogels and DOX-loaded 
nanogels maintained cell viability (Figures 11a, 12a). MTT assays quantified that the 
solutions of free DOX significantly (p<0.0001) reduced preosteoblast and osteosarcoma 
viability in comparison to the DOX-loaded nanogels and nanocomposites (Figures 11b, 
12b). 
Figure 10 – MOS-J IC-50 plot. IC-50 curve for MOS-J cell line when exposed to varying concentrations of DOX. Concentrations above 10 µg/mL DOX were sufficient for killing over 50% of these cells. 
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Figure 11 – Mouse osteosarcoma (MOS-J) cell line exposure studies. (a) Live/Dead staining of MOS-Js showed viability of all components of the nanocomposite in comparison to a solution of DOX (Free DOX). (b) Quantifiable viability was gathered via MTT assays. A significant difference (p<0.0001) was shown between free DOX and all other samples. DOX-loaded nanogels also showed the same significant differen ce with gel and DOX-loaded nanocomposites. 
Figure 12 – Mouse preosteoblast (MC3T3) cell line exposure studies. (a) Live/Dead staining of MC3T3s showed viability of all components of the nanocomposite in comparison to a solution of DOX (Free DOX). (b) Quantifiable viability was gathered via MTT assays. A significant difference (p<0.0001) was shown between free DOX and all other samples.  
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When comparing between the two cell types, viability was shown to be lower on 
average for MOS-J cells exposed to DOX-loaded nanogels than for the same sample type 
exposed to MC3T3 cells (Figure 13). This is in line with work by Maiorano et al., who 
explored the effects of viability on two cell types grown with different media that uptake 
the same amount and type of nanoparticles. [71] There is also the chance that some DOX 
was adhered to the surface instead of loaded fully within the nanogels. However, by 
suspending and fixating the nanogels within the gel matrix, we have shown that we can 
prevent this viability difference while still releasing DOX. Exposure of the DOX-loaded 









To develop a new drug delivery construct, PNIPAM-co-AM/MNP nanogels were 
synthesized and characterized to be functional and controlled in a regulated manner. It has 
been shown that we can synthesize citric acid-coated Fe3O4 nanoparticles, have them 
encapsulated by a thermoresponsive copolymer of PNIPAM-co-AM with a VPTT 
behavior of around 45 C. With these nanogels, we were able to show a large burst release 
of Doxorubicin at a temperature higher than the VPTT, and very limited release under this 
temperature. When these nanogels were exposed to healthy and cancerous cells, we 
showed that cells remained highly viable, thus showing controllability of release at body 
temperature. We were also able to show that these nanogels can release DOX into 
surrounding cells even after incorporation into a crosslinked gelatin-based hydrogel. 
Although the construct would only be injected into already existing or excised tumor sites, 
if any of the drug-loaded nanogels come loose due to simple physical fixation, the 
localized external application of AMF is hypothesized to prevent release from elsewhere 
in the body. In order to mitigate this possibility, nanogels could be functionalized and 
chemically attached to the macroscopic gel. Finally, our nanocomposite was exposed to 
an AMF like one presented by an MRI and a preliminary study showed a distinct increase 
in DOX release versus a nanocomposite not exposed to an AMF. 
In the future, looking at changing AMF intensity and frequency and increasing 
sample size would be beneficial to optimizing drug delivery out of the already implanted 
construct. Commercial MRIs found in many patient hospitals produce a field strength 
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ranging from 0.05 to 3 T. Our calculations showed that we were below this range, which 
allows the ability for us to continue working under the premise that this nanocomposite 
will work for biomedical applications and gives us the potential to expose the 
nanocomposite construct with a higher field for faster release. Collaboration with a 
laboratory or clinic with an MRI machine would allow us to compare the results from our 
induction heating system with a commercial standard in providing external magnetic 
stimuli process to get maximal drug delivery from our construct.  
Although addition of 5 mg nanogel to the 1 mL solution of 5 wt% gel showed no 
true difference in rheological characteristics, It is well documented that addition of 
nanoparticles alters these properties, so future studies would be done in order to test 
optimal release profiles in a more realistic tumor model where more cells would be present 
and release from a larger system would vary. [52] Therefore, altering weights of nanogels 
exposed to cells and altering number of cells can give us a better picture of the amount of 
nanogels required to have sufficient coverage of a quantifiable tissue area.  
We also recognize that this drug delivery system limits our potential market size 
to those without metallic implants due to the risks that an AMF has on metallic 
compounds. However, we feel that the market is sizeable enough that this gives us a decent 
entry point if this construct is pushed forward to further testing for market approval. A full 
market analysis of patients that this construct can help can also be performed in the future 
if needed. Instead of limiting our market to just patients with cancer, this nanocomposite 
construct can be loaded with any drug or combination of drugs to treat various medical 
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pathologies. Having potential to apply growth factors to this construct to regenerate tissue, 
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